
3i and Cathay invest combined €180m in Ponroy
3i Group and Cathay Capital have invested a combined €180m in healthcare group Ponroy Santé, together taking a majority stake in the group.
As a result of the transaction, 3i will hold a majority stake in the group. Company executives Fabrice Cahierc (CEO), Philippe Charrier (executive chairperson) and Arnaud Ponroy (former executive chairperson) will also retain interests in the company. Cahierc and Ponroy were previously invested in the group, while Charrier is a new shareholder.
3i invested in equity from its own balance sheet, contributing a total of €150m to the round, while Cathay invested €30m. According to the GP, Ponroy has registered a 10% annual growth rate over the last four years.
3i and Cathay said in a statement they would build on the company's strength in Europe, and further develop its global presence. Ponroy Santé already has a presence in Asia (Hong-Kong, China) and the Americas. Sino-French GP Cathay is expected to play a key role in the group's expansion into the Asian market.
Debt
A debt package was provided by Natixis, BNP Paribas, Societe Generale, Bank of Ireland, ING and HSBC to support the transaction.
Company
Founded in 1975 and headquartered in Boufféré, near Nantes, Ponroy Santé manufactures a range of natural healthcare and cosmetics products from functional and natural food supplements to natural cosmetics and hygiene products for babies and women. The group distributes its products through a chain of retailers, pharmacies, and drugstores, as well as through online sales.
Ponroy Santé operates under several brands, including Biolane, Yves Ponroy, Vitarmonyl, Manhae, Lecitone, Force G, Ultrabiotique and Naturé Moi. It manufactures most of its products in its French production plant, and exports products to 50 countries worldwide, with 35% of its sales coming from exports. According to the GP, the group currently generates €170m in revenues with EBITDA of €25m.
People
3i Group – Rémi Carnimolla (managing director); Guillaume Basquin (director).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater